U.S. markets closed


IOB - IOB Delayed Price. Currency in EUR
Add to watchlist
111.10-0.78 (-0.69%)
At close: 4:45PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close111.88
Bid110.15 x 0
Ask112.25 x 0
Day's Range110.20 - 111.60
52 Week Range101.75 - 144.80
Avg. Volume22,113
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      Drugs standards group nixes plan to kick pharma's crab blood habit

      Horseshoe crabs' icy-blue blood is set to remain the drug industry's standard for safety tests after a powerful U.S. group ditched a plan to put on an equal footing a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups. The crabs' copper-rich blood clots in the presence of bacterial endotoxins and has long been used in tests to detect contamination in shots and infusions. More recently, man-made versions called recombinant Factor C (rFC) from Basel-based Lonza and others have emerged.

    • bioMérieux S.A. (EPA:BIM) Earns A Nice Return On Capital Employed
      Simply Wall St.

      bioMérieux S.A. (EPA:BIM) Earns A Nice Return On Capital Employed

      Today we'll look at bioMérieux S.A. (EPA:BIM) and reflect on its potential as an investment. Specifically, we're going...

    • Reuters

      BioMerieux COVID testing product gets U.S. emergency use authorization

      Biomérieux, a French healthcare company specialising in diagnostics, said on Monday it had won more positive feedback from the U.S. Food & Drug Administration (FDA) regulator for its product aimed at helping test for the coronavirus. BioMerieux said its 'BIOFIRE® RP2.1' panel testing product, which includes 22 pathogens that cause respiratory infections including SARS-CoV-2 which causes the COVID-19 coronavirus, had won 'emergency use authorisation' from the FDA.